Dynamics and control of a mathematical model for metronomic chemotherapy

Mathematical Biosciences and Engineering : MBE
Urszula LedzewiczHeinz Schättler

Abstract

A 3-compartment model for metronomic chemotherapy that takes into account cancerous cells, the tumor vasculature and tumor immune-system interactions is considered as an optimal control problem. Metronomic chemo-therapy is the regular, almost continuous administration of chemotherapeutic agents at low dose, possibly with small interruptions to increase the efficacy of the drugs. There exists medical evidence that such administrations of specific cytotoxic agents (e.g., cyclophosphamide) have both antiangiogenic and immune stimulatory effects. A mathematical model for angiogenic signaling formulated by Hahnfeldt et al. is combined with the classical equations for tumor immune system interactions by Stepanova to form a minimally parameterized model to capture these effects of low dose chemotherapy. The model exhibits bistable behavior with the existence of both benign and malignant locally asymptotically stable equilibrium points. In this paper, the transfer of states from the malignant into the benign regions is used as a motivation for the construction of an objective functional that induces this process and the analysis of the corresponding optimal control problem is initiated.

References

Oct 1, 1990·Mathematical Biosciences·G W Swan
Mar 1, 1988·The British Journal of Radiology·J A O'Donoghue, T E Wheldon
Mar 1, 1994·Bulletin of Mathematical Biology·V A KuznetsovA S Perelson
May 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S D WeitmanB A Kamen
Apr 20, 2000·The Journal of Clinical Investigation·D HanahanE Bergsland
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B A KamenE Glatstein
Mar 17, 2004·Journal of Theoretical Biology·Harold P de Vladar, Jorge A González
Nov 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristian Pietras, Douglas Hanahan
May 4, 2007·The Journal of Clinical Investigation·Jeremy B Swann, Mark J Smyth
Jun 3, 2009·Cancer Research·Robert A GatenbyB Roy Frieden
Nov 13, 2009·Bulletin of Mathematical Biology·Yangjin Kim, Avner Friedman
Jul 1, 2005·Mathematical Biosciences and Engineering : MBE·Urszula ForysYuri Kogan
Jun 10, 2010·Nature Reviews. Clinical Oncology·Eddy PasquierNicolas André
May 10, 2011·Journal of Mathematical Biology·Urszula LedzewiczHeinz Schättler
Jul 16, 2013·Journal of Theoretical Biology·Sébastien Benzekry, Philip Hahnfeldt
Aug 3, 2013·Mathematical Biosciences and Engineering : MBE·Baba Issa CamaraEvans K Afenya
Aug 3, 2013·Mathematical Biosciences and Engineering : MBE·Urszula LedzewiczHeinz Schättler
Jun 11, 2014·Nature Reviews. Clinical Oncology·Nicolas AndréEddy Pasquier
Aug 30, 2014·Cancer Letters·Yi-Bin HaoKe-Jun Nan
Jun 20, 2015·Journal of Mathematical Biology·Heinz SchättlerBehrooz Amini

❮ Previous
Next ❯

Citations

Sep 1, 2019·Bulletin of Mathematical Biology·Artur César Fassoni, Denis Carvalho Braga
Oct 25, 2016·Mathematical Biosciences and Engineering : MBE·Ami B ShahJana L Gevertz
Nov 24, 2016·Mathematical Biosciences and Engineering : MBE·Urszula LedzewiczEddy Pasquier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Related Papers

Mathematical Biosciences and Engineering : MBE
Jan PoleszczukUrszula Foryś
Onkologie
Roberta Sarmiento, Giampietro Gasparini
Computational and Mathematical Methods in Medicine
Marzena Dołbniak, Andrzej Swierniak
© 2022 Meta ULC. All rights reserved